Results 81 to 90 of about 164,596 (212)

Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis

Neoplasia: An International Journal for Oncology Research
Background: Cisplatin resistance is one of the major obstacles in non-small cell lung cancer (NSCLC) treatment. Intriguingly, elevated lactate levels were observed in cisplatin-resistant cells, which spurred further investigation into their underlying ...
Wei Bo, Ning Yu, Xiaokai Wang, Chun Wang, Chunying Liu   +4 more
doaj   +1 more source

Organometallic iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis [PDF]

, 2013
Platinum complexes related to cisplatin, cis-[PtCl2(NH3)2], are successful anticancer drugs; however, other transition metal complexes offer potential for combating cisplatin resistance, decreasing side effects, and widening the spectrum of activity ...
Bailey H. H., Ballestrero A., Bellamy W. T., Betanzos-Lara S., Bozic I., Bushra Qamar, Carew J. S., Castonguay A., Chan J., Constantini P., Dai Y., Degterev A., Dindo D., Doroshow J. H., Dyke M. W. Van, Fagan V., Finnilä S., Frank J. E., Fu Y., Fu Y., Gaiddon C., Garbutcheon-Singh K. B., Hannon M. J., Hartinger C. G., Hileman E. A., Holbeck S., Huo H., Ian Hands-Portman, Isolda Romero-Canelón, Jessica M. Hearn, Jordan M. A., Jungwirth U., Kelland L., Kerr J. F., Kroemer G., Lazebnik Y. A., Liu Z., Liu Z., Liu Z., Lu J.-J., McKeage M. J., Millar A. W., Monneret C., Nagata S., Park G. Y., Paull K., Perchellet E. M., Peter J. Sadler, Petrelli A., Pittella F., Porteous C. M., Pracharova J., Purewal M., Rai S. S., Rixe O., Saraste A., Shoemaker R. H., Shoemaker R. H., Siddik Z., Sidler D., Tsutsui T., Türk D., Van den Bogert C., Zalacaín M., Zhang Y.-W., Zhe Liu, Zhou D.-F., Zhu Z.   +67 more
core   +1 more source

MECHANISM OF APOPTOSIS INHIBITION TO SQUAMOUS CELL CARCINOMA OF ORAL CANCER IN CISPLATIN TREATMENT

Folia Medica Indonesiana, 2017
This study was to approve the increased secretion of Hsp 70, DNA damage, and inhibitor apoptosis protein in cisplatin therapy which influence apoptosis of oral cancer cell and to know mechanism of molecular pathology.
R Marjono Dwi Wibowo, David S Perdanakusuma, Eddy Herman Tanggo   +2 more
doaj   +1 more source

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer [PDF]

, 2012
Carboplatin remains a first-line agent in the management of epithelial ovarian cancer (EOC). Unfortunately, platinum-resistant disease ultimately occurs in most patients.
A Bali, C Beretta, D P Lovell, E Papacharalbous, E Rosenberg, G D’Andrilli, H M Coley, HM Coley, I-S Song, K Madhuri, MA Levesque, N A M Safuwan, N Syed, N Syed, P Chivers, P Vlachos, P Zhang, PS Larson, RM Glasspool, S Butler-Manuel, SH Wei, ST Kim, T Crook, T Giannopoulos, T Kobatake, V Masciullo, W Roeb, Y Ma   +27 more
core   +1 more source

Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53 [PDF]

, 2012
Bovine papillomavirus type 1 infects not only cattle but also equids and is a causative factor in the pathogenesis of commonly occurring equine sarcoid tumours.
Campo, M., Finlay, M., Morgan, I.M., Nasir, L., Yuan, Z.   +4 more
core   +3 more sources

NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis

Cancer Management and Research, 2020
Mingzhe Zhu,1,* Lei Yang,2,* Xin Wang3 1Department of Obstetrics and Gynecology, Jilin Medical College Affiliated Hospital, Jilin City, Jilin Province 132011, People’s Republic of China; 2Department of Medical Clinic, Yuhuangding Hospital, Yantai ...
Zhu M, Yang L, Wang X
doaj  

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. [PDF]

, 2019
Gene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence.
Anderson, Kristen, Barrie, Allison M, Bean, Lisa M, Chen, Xiao Lei, Connolly, Denise C, Cordasco, Edward A, Diaz Osterman, Carlos J, Fisch, Kathleen M, Fu, Guo, Győrffy, Balázs, Heino, Jyrki, Jean, Christine, Jiang, Shulin, Kleinschmidt, Elizabeth G, Kolev, Vihren N, Li, Jian, Mark, Adam M, McHale, Michael T, Molinolo, Alfredo, Ojalill, Marjaana, Ozmadenci, Duygu, Pachter, Jonathan A, Rappu, Pekka, Schlaepfer, David D, Stupack, Dwayne G, Sulzmaier, Florian J, Tancioni, Isabelle, Taylor, Kristin N, Uryu, Sean, Weaver, David T, Xu, Guorong   +30 more
core   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Relationship between chronological aging and acquired resistance to cisplatin in the yeast saccharomyces cerevisiae [PDF]

, 2019
The Sir2 gene is associated with an increase in longevity in yeasts, worms, flies and rodents. The human homolog, Sirt1, is also involved in longevity, by inhibiting cellular senescence.
Burgos-Molina, Antonio Manuel, Gil-Carmona, Luisa, Mercado-Sáenz, Silvia, Ruiz-Gomez, Miguel Jose   +3 more
core  

Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer [PDF]

, 2007
Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease.
Fasching, P. A., Heinemann, Volker, Kalischefski, B., Koelbl, H., Laessig, D., Maubach, P., Meerpohl, H., Melchert, F., Morack, G., Scharl, A., Stauch, M., Stemmler, H. J., Vehling-Kaiser, U., Weber, B.   +13 more
core   +1 more source